Biocept reports unaudited 2021 revenue and year-end cash balance

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of december 31, 2021 of approximately $28 million. “revenue reached a record high in 2021, up 123% over the prior year driven primarily by rt-pcr covid-19 testing. as anticipated, we are currently experiencing a decline in covid-19 testing demand as the unpredictable pandemic b
BIOC Ratings Summary
BIOC Quant Ranking